The cervical cancer epidemic that screening has prevented in the UK
- PMID: 15262102
- DOI: 10.1016/S0140-6736(04)16674-9
The cervical cancer epidemic that screening has prevented in the UK
Abstract
Background: Recent reports suggest that the reduction in mortality achieved by the UK national cervical screening programme is too small to justify its financial and psychosocial costs, except perhaps in a few high-risk women.
Methods: We analysed trends in mortality before 1988, when the British national screening programme was launched, to estimate what future trends in cervical cancer mortality would have been without any screening.
Findings: Cervical cancer mortality in England and Wales in women younger than 35 years rose three-fold from 1967 to 1987. By 1988, incidence in this age-range was among the highest in the world despite substantial opportunistic screening. Since national screening was started in 1988, this rising trend has been reversed.
Interpretation: Cervical screening has prevented an epidemic that would have killed about one in 65 of all British women born since 1950 and culminated in about 6000 deaths per year in this country. However, these estimates are subject to substantial uncertainty, particularly in relation to the effects of oral contraceptives and changes in sexual behaviour. 80% or more of these deaths (up to 5000 deaths per year) are likely to be prevented by screening, which means that about 100000 (one in 80) of the 8 million British women born between 1951 and 1970 will be saved from premature death by the cervical screening programme at a cost per life saved of about pound 36000. The birth cohort trends also provide strong evidence that the death rate throughout life is substantially lower in women who were first screened when they were younger.
Comment in
-
Modelling the effect of screening for cervical cancer on the population.Lancet. 2004 Jul 17-23;364(9430):224-6. doi: 10.1016/S0140-6736(04)16687-7. Lancet. 2004. PMID: 15262081 No abstract available.
-
Harms and benefits of screening to prevent cervical cancer.Lancet. 2004 Oct 23-29;364(9444):1483-4; author reply 1485-6. doi: 10.1016/S0140-6736(04)17260-7. Lancet. 2004. PMID: 15500881 No abstract available.
-
Harms and benefits of screening to prevent cervical cancer.Lancet. 2004 Oct 23-29;364(9444):1483; author reply 1485-6. doi: 10.1016/S0140-6736(04)17259-0. Lancet. 2004. PMID: 15500882 No abstract available.
-
Harms and benefits of screening to prevent cervical cancer.Lancet. 2004 Oct 23-29;364(9444):1484-5; author reply 1485-6. doi: 10.1016/S0140-6736(04)17261-9. Lancet. 2004. PMID: 15500883 No abstract available.
-
Harms and benefits of screening to prevent cervical cancer.Lancet. 2004 Oct 23-29;364(9444):1485; author reply 1485-6. doi: 10.1016/S0140-6736(04)17262-0. Lancet. 2004. PMID: 15500885 No abstract available.
Similar articles
-
Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.Acta Oncol. 1997;36 Suppl 9:1-60. Acta Oncol. 1997. PMID: 9143316
-
The impact of a two- versus three-yearly cervical screening interval recommendation on cervical cancer incidence and mortality: an analysis of trends in Australia, New Zealand, and England.Cancer Causes Control. 2013 Sep;24(9):1727-36. doi: 10.1007/s10552-013-0250-9. Epub 2013 Jul 6. Cancer Causes Control. 2013. PMID: 23832659
-
Cervical screening in England and Wales: its effect has been underestimated.Cytopathology. 2000 Dec;11(6):471-9. doi: 10.1046/j.1365-2303.2000.00272.x. Cytopathology. 2000. PMID: 11194078
-
Cervical cancer screening. Organised screening to avoid unnecessary conisation.Prescrire Int. 2010 Aug;19(108):172-7, 179. Prescrire Int. 2010. PMID: 20939454 Review.
-
Cervical cancer.Cancer Surv. 1994;19-20:265-85. Cancer Surv. 1994. PMID: 7534630 Review.
Cited by
-
Human papillomavirus vaccine: a boon or curse.Hum Vaccin Immunother. 2014;10(12):3509-12. doi: 10.4161/21645515.2014.980689. Hum Vaccin Immunother. 2014. PMID: 25668662 Free PMC article.
-
Personal factors influence use of cervical cancer screening services: epidemiological survey and linked administrative data address the limitations of previous research.BMC Health Serv Res. 2012 Feb 14;12:34. doi: 10.1186/1472-6963-12-34. BMC Health Serv Res. 2012. PMID: 22333392 Free PMC article.
-
The vaginal microbiota, high-risk human papillomavirus infection, and cervical cytology: results from a population-based study.Gynecol Pelvic Med. 2020 Sep;3:18. doi: 10.21037/gpm-20-10. Gynecol Pelvic Med. 2020. PMID: 35252846 Free PMC article.
-
Monitoring HPV16/18 immunisation in England and elsewhere.Br J Cancer. 2010 Jul 13;103(2):157-8. doi: 10.1038/sj.bjc.6605758. Br J Cancer. 2010. PMID: 20628394 Free PMC article. No abstract available.
-
Association Between HIV Infection and Cancer Stage at Presentation at the Uganda Cancer Institute.J Glob Oncol. 2018 Sep;4:1-9. doi: 10.1200/JGO.17.00005. Epub 2017 Oct 16. J Glob Oncol. 2018. PMID: 30241147 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical